Durvalumab and Tremelimumab in Resectable HCC

Clinical trial NCT05440864 · RECRUITING

Trial details

NCT number: NCT05440864
Sponsor: University Health Network, Toronto
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2023-10-26
Primary completion: 2025-11-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.